Lead Product(s) : Capeserod
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
Details : Under the terms of the agreement, First Wave will receive from Sanofi an exclusive, global license for Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for gastrointestinal (GI) indications.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 14, 2023
Lead Product(s) : Capeserod
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tilray Medical Shares Positive Oral Cannabis Extract Data for Chemotherapy-Induced Emesis
Details : Tilray Medical aimed to test the effectiveness of an oral cannabis extract in adults suffering from chemotherapy-induced nausea and vomiting despite standard anti-nausea treatments.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 07, 2024
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : INF108
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Infinant Health Announces Submission of Orphan Drug Designation Application
Details : Infinant Health's patented drug candidate is a Bifidobacterium longum subspecies infantis strain, INF108, being developed for the prevention of necrotizing enterocolitis in pre-term infants.
Brand Name : INF108
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 02, 2024
Lead Product(s) : INF108
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AstraGin
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NuLiv Science demonstrate the potential of AstraGin® to support overall gut health and well-being, positioning it as a promising solution for individuals with UC and other gut-related challenges.
Brand Name : AstraGin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 03, 2023
Lead Product(s) : AstraGin
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rifaximin
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XIFAXAN (rifaximin) is a 2 week prescription treatment that provided up to 6 months of relief from IBS-D symptoms of abdominal pain and diarrhea in a clinical trial.
Brand Name : Rifaximin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 11, 2022
Lead Product(s) : Rifaximin
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Kratom Extract
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum
Details : Tauriga commenced the development of a proprietary Kratom extract infused supplement chewing gum for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 07, 2021
Lead Product(s) : Kratom Extract
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Napo EU
Deal Size : $5.0 million
Deal Type : Agreement
Details : Mytesi, only oral plant-based prescription medicine approved under FDA Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit ...
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2021
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Napo EU
Deal Size : $5.0 million
Deal Type : Agreement
Lead Product(s) : HT-003
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Isoprene Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Hoth plans to investigate the therapeutic potential of the HT-003 API using relevant ex vivo tissue models and other in vitro molecular studies.
Brand Name : HT-003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 18, 2021